HOME/INDUSTRIES/

Life Sciences & Biotech

LIFE SCIENCES

Every dollar you spend on finance is a dollar not spent on the science.

We partner with executives and finance teams across biotech, pharma, and medtech. Clients use our fractional and interim life science CFOs and outsourced accounting to get senior expertise without expanding headcount during the stages where headcount is most expensive, from pre-funded start-up to post-IPO.

Talk to Kevin

What we solve here

YOUR CFO

Kevin Sarney, CPA, MBA

Life Sciences Practice Leader

Kevin serves as life sciences CFO for our clients, with more than 20 years in public and private life science companies. He has taken organizations through raises, financial controls, audits, and SEC reporting, and supports finance operations from drug development through product launch.

20+ YEARS · PUBLIC AND PRIVATE LIFE SCIENCE

FULL BENCH →

THE PRESSURE, NAMED

The financial complexity of a clinical-stage company does not scale with its headcount.

Select a pressure to see how the engagement answers it.

Burn and runway How long does our money last, and what does the next milestone actually cost? Capital-intensive planning and multi-scenario models built around your development plan, not a generic template. You get a runway number you can defend to a board and revise when the science changes.

Budgeting that eats the team Budgeting takes weeks, and by the time it is done the assumptions have moved.. We take on the labor-intensive budgeting and multiple-scenario planning that a lean team cannot absorb, so your scientists and executives stop building spreadsheets and start reviewing them.

Long R&D cycles Our project cycles run for years. Standard accounting does not fit them. Accounting and forecasting built for long-term R&D project cycles, including accruals for clinical work, contract research spend, and the milestone structures your agreements actually use.

Audit, SEC, and the board We have an audit and a filing deadline, and no one internally has done this before. Audit readiness, financial controls, and SEC reporting run by people who have filed before. Institutional-grade books, and a closing binder that becomes the single source of truth for internal reporting and external audit.

Post-IPO reporting We are public now, and the reporting burden just tripled. Fractional finance support that lets a small organization operate as a fully public company, without building a full-time finance and accounting department to do it.

WHAT IT SOUNDS LIKE

HOW WE ANSWER IT

WHAT WE OWN IN THIS INDUSTRY

From pre-funded start-up to post-IPO, without a headcount build.

Flexible, experienced, senior financial expertise, with the specialized knowledge the sector requires.

Flexible, experienced, senior financial expertise on a fractional or interim basis.
Reduced cost against a full-time finance and accounting build.
Specialized life sciences knowledge and training, not general business accounting.
No headcount expansion during critical growth stages.
Labor-intensive budgeting and multiple-scenario planning.
Long-term R&D project cycle accounting.
Capital-intensive planning and runway modeling.
Financial raises, financial controls, audits, and SEC reporting.
Support from drug development through product launch.
Post-IPO financial reporting on a fractional model.

Delivered through

Fractional CFO

Interim CFO

Outsourced Accounting

AI-Enabled Finance

Financial Consulting

Tax Consulting

WHO WE HAVE DONE THIS FOR

Biotech, pharma, and medtech organizations that have used this bench.

We outsourced our complete accounting and finance function for the life of our biotech company, from inception to even after we were acquired by Celgene. Charles River CFO provided exceptional service throughout.

Jay Mohr

Founder and former CEO

GLOUCESTER PHARMACEUTICALS